A public meeting to discuss the unmet need for new therapies to treat OA was held on May 16, 2019 in Washington with 80 people attending in person or via webex.  The speaker slides are now available. See link below. 

The Pre-Competitive Consortium for OA (PCCOA) was created by OARSI more than a decade ago in response to a Federal Register Notice seeking a critical appraisal on a number of questions that would help to inform the updating of the 1999 guidance for Clinical Development Programs for the Treatment and Prevention OA.  Subsequently in 2016, OARSI submitted a White Paper to the FDA providing a comprehensive review and rationale for OA to be defined as a potentially serious disease...

OARSI wishes to thank OARSI members  Hiral Master, Louise Thoma and Linda Truong for their outstanding work to produce the OARSI infographic on OA as a Serious Disease based on the OARSI White Paper.  A slide deck is now available as well as two versions of the infographic that can be printed. Please feel free to use the slides in your talks and share/print the infographic.

Pfizer Inc. and Eli Lilly and Company are pleased to announce the call for proposals for the 2nd Global Awards for Advancing Chronic Pain Research (ADVANCE) in 2019. ADVANCE is an independently-reviewed, competitive grants program. The mission of the program is to fund innovative, novel research proposals that seek to advance the understanding and management of chronic pain.  

Proposals will be reviewed by an external, Independent Review Committee comprising renowned, global experts in chronic pain and will be reviewed based on area of interest, originality, scientific merit, and feasibility. The program will fund...

Application deadline: August 8, 2019

Learn More about OARSI